JP2022539585A5 - - Google Patents

Info

Publication number
JP2022539585A5
JP2022539585A5 JP2022500080A JP2022500080A JP2022539585A5 JP 2022539585 A5 JP2022539585 A5 JP 2022539585A5 JP 2022500080 A JP2022500080 A JP 2022500080A JP 2022500080 A JP2022500080 A JP 2022500080A JP 2022539585 A5 JP2022539585 A5 JP 2022539585A5
Authority
JP
Japan
Application number
JP2022500080A
Other languages
Japanese (ja)
Other versions
JP7834016B2 (ja
JP2022539585A (ja
JPWO2021005339A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2020/051594 external-priority patent/WO2021005339A1/en
Publication of JP2022539585A publication Critical patent/JP2022539585A/ja
Publication of JP2022539585A5 publication Critical patent/JP2022539585A5/ja
Publication of JPWO2021005339A5 publication Critical patent/JPWO2021005339A5/ja
Application granted granted Critical
Publication of JP7834016B2 publication Critical patent/JP7834016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022500080A 2019-07-05 2020-07-03 新規な癌抗原及び方法 Active JP7834016B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19184742 2019-07-05
EP19184742.5 2019-07-05
PCT/GB2020/051594 WO2021005339A1 (en) 2019-07-05 2020-07-03 Novel cancer antigens and methods

Publications (4)

Publication Number Publication Date
JP2022539585A JP2022539585A (ja) 2022-09-12
JP2022539585A5 true JP2022539585A5 (https=) 2023-07-13
JPWO2021005339A5 JPWO2021005339A5 (https=) 2023-07-13
JP7834016B2 JP7834016B2 (ja) 2026-03-23

Family

ID=67211535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500080A Active JP7834016B2 (ja) 2019-07-05 2020-07-03 新規な癌抗原及び方法

Country Status (11)

Country Link
US (1) US20220211760A1 (https=)
EP (1) EP3994156A1 (https=)
JP (1) JP7834016B2 (https=)
KR (1) KR20220034039A (https=)
CN (2) CN114174323B (https=)
AU (1) AU2020312230A1 (https=)
BR (1) BR112022000133A2 (https=)
CA (1) CA3141990A1 (https=)
IL (1) IL289334A (https=)
MX (1) MX2022000262A (https=)
WO (1) WO2021005339A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006941A2 (pt) 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的hla展示肽
US20250054576A1 (en) 2021-12-17 2025-02-13 Evaxion Biotech A/S Personalized cancer therapy targeting normally non-expressed sequences
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US20020015998A1 (en) 2000-04-06 2002-02-07 Gabriel Vogeli Novel G protein-coupled receptors
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
AT502292B1 (de) 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
US20100120627A1 (en) * 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
WO2009026116A2 (en) * 2007-08-16 2009-02-26 Genizon Biosciences, Inc. Genemap of the human genes associated with longevity
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
CR20180551A (es) * 2016-04-21 2019-02-12 Immatics Biotechnologies Gmbh Inmunoterapia contra el melanoma y otros tipos de cáncer
US10384736B2 (en) * 2016-07-13 2019-08-20 Marcelo A. Pizarro Dual oscillating cycle saddle and support system

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)